Table 2.
Indications for Prescribing Pharmacotherapy with New Evidence-Based Cardiovascular Indications in our Center for Preventive Cardiology.
| Indication | PCSK9i | EPA | SGLT2i | GLP-1 RA |
|---|---|---|---|---|
| LDL-C lowering | ✓ | |||
| Triglyceride lowering | ✓ | |||
| Glucose lowering | ✓ | ✓ | ||
| Weight loss | ✓ | ✓ | ||
| ASCVD | ✓ | ✓ | ✓ | ✓ |
| HFrEF | ✓ |
ASCVD, atherosclerotic cardiovascular disease; HFrEF, heart failure with reduced ejection fraction; EPA, eicosapentaenoic acid; GLP-1 RA, glucagon-like peptide-1 receptor agonists; LDL-C, low-density lipoprotein cholesterol; PCSK9i, protein convertase subtilisin/kexin type 9 inhibitors; SGLT2i, sodium-glucose cotransporter 2 inhibitors.